A Phase I/II, Single Center, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above

The purpose of this study is to assess the safety and immunogenicity of two dose levels of the single dose Recombinant RSV vaccine(CHO cells), when administered intramuscularly (IM) in healthy adults aged 18 years and older.

Start Date13 Nov 2024

Sponsor / Collaborator

Chengdu Maxvax Biotechnology LLC

[+1]

ITMCTR2024000513

/ RecruitingNot Applicable

Study on the improvement of functional constipation with chicory and poria composite dietary fiber

Start Date08 Oct 2024

Sponsor / Collaborator

Henan Center For Disease Control & Prevention

100 Clinical Results associated with Henan Center For Disease Control & Prevention

0 Patents (Medical) associated with Henan Center For Disease Control & Prevention

467

Literatures (Medical) associated with Henan Center For Disease Control & Prevention

10 Apr 2025·Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi

[Awareness of HCV infection status and willingness for ribonucleic acid testing among hepatitis C cases in four provinces in China].

Article

Author: Han, J ; Tang, H ; Li, N ; Liu, Z F ; Ye, S D ; Yu, J J ; Yang, D D ; Li, J ; Zhang, X B

Objective: To analyze the awareness of HCV infection status and willingness for HCV-RNA testing among hepatitis C cases in four provinces in China and to provide a reference for adjusting HCV prevention and control strategies. Methods: From September 2021 to September 2022, a cross-sectional survey was conducted using stratified random cluster sampling in four provinces (Jiangsu, Henan, Hubei, and Yunnan) in China, with an estimated sample size of 6 468 participants. The questionnaire included sociodemographic information, HCV infection awareness, willingness for HCV-RNA testing, and history of high-risk behaviors from the survey participants. Logistic regression models were used to analyze the factors associated with HCV infection awareness and willingness for HCV-RNA testing among hepatitis C cases. Statistical analysis was performed using R 4.1.3 software. Results: A total of 10 563 hepatitis C cases were surveyed. The awareness rate of HCV infection was 86.74% (9 162/10 563), and the willingness rate for HCV-RNA testing was 85.21% (9 001/10 563). Multivariate logistic regression models analysis showed that the awareness rate of HCV infection was lower among individuals aged ≥60 years, urban residents (with New Rural Cooperative Medical Insurance ), those without a history of blood transfusion, those without a history of paid blood donation, those without a history of injection drug use, and those without a family member with hepatitis C case.The awareness rate was higher among individuals with high or technical secondary school education, college education or above, and those married with a spouse (all P<0.05). In terms of willingness for HCV-RNA testing, it was lower among females, individuals aged ≥60 years, and those without a history of blood transfusion, paid blood donation, or injection drug use. The willingness was higher among farmers or migrant workers, employees of enterprises or institutions, and those in other occupations (all P<0.05). Conclusions: There was room for improvement in the awareness proportion of HCV infection and willingness for HCV-RNA testing among hepatitis C cases in the four provinces of China. More convenient policies and measures should be provided to increase the awareness rate of HCV infection and the willingness to undergo HCV-RNA testing in this population.

01 Apr 2025·Journal of Virological Methods

Development and implementation of a novel method for detecting hepatitis C virus resistance-associated substitutions to NS3, NS5A, and NS5B inhibitors in Linzhou, China

Article

Author: Nie, Yugang ; Li, Jian ; Zhang, Cui ; Han, Mengjie ; Liu, Yuqiu ; Li, Ning ; Qin, Rong ; Qiu, Maofeng ; Xing, Wenge ; Ji, Xiaoyu ; Liu, Zhongfu

BACKGROUNDHepatitis C virus (HCV) resistance-associated substitutions (RASs) have a significant impact on the treatment of HCV with direct-acting antivirals (DAAs). However, limited research has been conducted, and no standardized methods for detecting RASs in mainland China.OBJECTIVESTo develop and apply a novel method for detecting HCV RASs in HCV RNA-positive patients in Linzhou, China.STUDY DESIGNIn total, 103 HCV RNA-positive serum specimens and epidemiological questionnaires were collected. A PCR method for detecting HCV RASs encompassing the NS3 to NS5B region was developed.RESULTSDemographic analysis revealed a predominance of females (66/103, 64.1 %), with an average age of 70 years. Genotype 1b (GT1b) (17/103, 16.5 %) and GT2a (86/103, 83.5 %) were identified. The prevalence of RASs was higher (17/17, 100 %) in GT1b than in GT2a (7/86, 8 %). In GT1b, a higher frequency of RASs was observed in the NS5B region (17/17, 100 %) than in the NS3 (14/17, 82 %) and NS5A (10/17, 59 %) regions. C316N was the most prevalent, followed by S122G (71 %) and R30Q (35 %).CONCLUSIONSWe introduced an innovative approach for the detection of HCV RASs and provided a wealth of information on HCV RASs in Linzhou, China. The findings support the cautious selection of treatment regimens, potentially improving patient outcomes.

01 Apr 2025·Vaccine

Corrigendum to “Antibody persistence in Chinese toddlers at 1 year and 2 years after two different 4-dose schedules of a novel 13-valent pneumococcal conjugate vaccine (PCV13-TT)” [Vaccine 49 (7) (2025) 126815]

Author: Lin, Jianxiang ; Li, Hong ; Shi, Lei ; Jiang, Zhiwei ; Fan, Huilan ; Yuan, Lin ; Chen, Jingjing ; Gao, Xuefen ; Xie, Zhiqiang ; Yang, Yemei ; Tao, Siwen ; Yue, Junyan ; Shi, Jing ; Huang, Zhen ; Yan, Xuemei ; Ye, Qiang ; Hu, Ruoyu

100 Deals associated with Henan Center For Disease Control & Prevention

100 Translational Medicine associated with Henan Center For Disease Control & Prevention

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 30 May 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Henan Center For Disease Control & Prevention

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 30 May 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing